BNBernhard Nieswandt

Bernhard Nieswandt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bernhard Nieswandt has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Hubert Zirngibl

    From the Department of Molecular Oncology, General Surgery, Witten/Herdecke University, Wuppertal, Germany; INSERM U.311, Etablissement Français du Sang-Alsace, Strasbourg Cedex, France; and Department of Molecular Pharmacology, University of Heidelberg, Heidelberg, Germany

    7 shared publications
  • Wolfgang Bergmeier

    From the Department of Molecular Oncology, General Surgery, Witten/Herdecke University, Wuppertal, Germany; INSERM U.311, Etablissement Français du Sang-Alsace, Strasbourg Cedex, France; and Department of Molecular Pharmacology, University of Heidelberg, Heidelberg, Germany

    7 shared publications
  • Kirsten Rackebrandt

    Department of Molecular Oncology, General Surgery, Witten/Herdecke University, 42117 Wuppertal, Germany

    4 shared publications
  • Valerie Schulte

    From the Department of Molecular Oncology, General Surgery, Witten/Herdecke University, Wuppertal, Germany; INSERM U.311, Etablissement Français du Sang-Alsace, Strasbourg Cedex, France; and Department of Molecular Pharmacology, University of Heidelberg, Heidelberg, Germany

    4 shared publications
  • Christian Gachet

    From the Department of Molecular Oncology, General Surgery, Witten/Herdecke University, Wuppertal, Germany; INSERM U.311, Etablissement Français du Sang-Alsace, Strasbourg Cedex, France; and Department of Molecular Pharmacology, University of Heidelberg, Heidelberg, Germany

    2 shared publications
  • Cord Brakebusch

    Biotech Research and Innovation Center (BRIC), University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen, Denmark

    2 shared publications

Latest Publications

  • Open Access

    Evidence for cross-talk between glycoprotein VI and Gi-coupled receptors during collagen-induced platelet aggregation

    by Bernhard Nieswandt, Wolfgang Bergmeier, Anita Eckly, Valerie Schulte, Philippe Ohlmann, Jean-Pierre Cazenave, Hubert Zirngibl, Stefan Offermanns, Christian Gachet

    Collagen-induced platelet aggregation is a complex process and involves synergistic action of integrins, immunoglobulin (Ig)-like receptors, G-protein–coupled receptors and their ligands, most importantly collagen itself, thromboxane A2(TXA2), and adenosine diphosphate (ADP). The precise role of each of these receptor systems in the overall processes of activation and aggregation, however, is still poorly defined. Among the collagen receptors expressed on platelets, glycoprotein (GP) VI has been identified to play a crucial role in collagen-induced activation. GPVI is associated with the FcRγ chain, which serves as the signal transducing unit of the receptor complex. It is well known that clustering of GPVI by highly specific agonists results in platelet activation and irreversible aggregation, but it is unclear whether collagen has the same effect on the receptor. This study shows that platelets from Gαq-deficient mice, despite their severely impaired response to collagen, normally aggregate on clustering of GPVI, suggesting this not to be the principal mechanism by which collagen activates platelets. On the other hand, dimerization of GPVI by a monoclonal antibody (JAQ1), which by itself did not induce aggregation, provided a sufficient stimulus to potentiate platelet responses to Gi-coupled, but not Gq-coupled, agonists. The combination of JAQ1 and adrenaline or ADP, but not serotonin, resulted in αIIbβ3-dependent aggregation that occurred without intracellular calcium mobilization and shape change in the absence of Gαq or the P2Y1 receptor. Together, these results provide evidence for a cross-talk between (dimerized) GPVI and Gi-coupled receptors during collagen-induced platelet aggregation.


  • Top Cited Papers
    Open Access

    Glycoprotein VI but not α2β1 integrin is essential for platelet interaction with collagen

    by Bernhard Nieswandt, Cord Brakebusch, Wolfgang Bergmeier, Valerie Schulte, Daniel Bouvard, Rabée Mokhtari‐Nejad, Theo Lindhout, Johan W.M. Heemskerk, Hubert Zirngibl, Reinhard Fässler

    Platelet adhesion on and activation by components of the extracellular matrix are crucial to arrest post‐traumatic bleeding, but can also harm tissue by occluding diseased vessels. Integrin α2β1 is thought to be essential for platelet adhesion to subendothelial collagens, facilitating subsequent interactions with the activating platelet collagen receptor, glycoprotein VI (GPVI). Here we show that Cre/loxP‐mediated loss of β1 integrin on platelets has no significant effect on the bleeding time in mice. Aggregation of β1‐null platelets to native fibrillar collagen is delayed, but not reduced, whereas aggregation to enzymatically digested soluble collagen is abolished. Furthermore, β1‐null platelets adhere to fibrillar, but not soluble collagen under static as well as low (150 s−1) and high (1000 s−1) shear flow conditions, probably through binding of αIIbβ3 to von Willebrand factor. On the other hand, we show that platelets lacking GPVI can not activate integrins and consequently fail to adhere to and aggregate on fibrillar as well as soluble collagen. These data show that GPVI plays the central role in platelet‐collagen interactions by activating different adhesive receptors, including α2β1 integrin, which strengthens adhesion without being essential.


  • Open Access

    Long-Term Antithrombotic Protection by in Vivo Depletion of Platelet Glycoprotein VI in Mice

    by Bernhard Nieswandt, Valerie Schulte, Wolfgang Bergmeier, Rabée Mokhtari-Nejad, Kirsten Rackebrandt, Jean-Pierre Cazenave, Philippe Ohlmann, Christian Gachet, Hubert Zirngibl

    Coronary artery thrombosis is often initiated by abrupt disruption of the atherosclerotic plaque and activation of platelets on the subendothelial layers in the disrupted plaque. The extracellular matrix protein collagen is the most thrombogenic constituent of the subendothelial layer; therefore, a selective inhibition of the collagen activation pathway in platelets may provide strong antithrombotic protection while preserving other platelet functions. Here we demonstrate that treatment of mice with a monoclonal antibody against the activating platelet collagen receptor glycoprotein VI (GPVI; JAQ1) results in specific depletion of the receptor from circulating platelets and abolished responses of these cells to collagen and collagen-related peptides (CRPs). JAQ1-treated mice were completely protected for at least 2 wk against lethal thromboembolism induced by infusion of a mixture of collagen (0.8 mg/kg) and epinephrine (60 μg/ml). The tail bleeding times in JAQ1-treated mice were only moderately increased compared with control mice probably because the treatment did not affect platelet activation by other agonists such as adenosine diphosphate or phorbol myristate acetate. These results suggest that GPVI might become a target for long-term prophylaxis of ischemic cardiovascular diseases and provide the first evidence that it is possible to specifically deplete an activating glycoprotein receptor from circulating platelets in vivo.


  • Open Access

    Rhodocytin (Aggretin) Activates Platelets Lacking α2β1 Integrin, Glycoprotein VI, and the Ligand-binding Domain of Glycoprotein Ibα

    by Wolfgang Bergmeier, Daniel Bouvard, Johannes A. Eble, Rabée Mokhtari-Nejad, Valerie Schulte, Hubert Zirngibl, Cord Brakebusch, Reinhard Fässler, Bernhard Nieswandt


    • 1 October 2000
      • Vol. 96  (7) , 2520-7

    Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice.

    by B Nieswandt, W Bergmeier, K Rackebrandt, J E Gessner, H Zirngibl

    The pathogenic effects of antiplatelet antibodies were investigated in mice. Monoclonal antibodies (mAbs) of different immunoglobulin G subclass directed against mouse GPIIbIIIa, GPIIIa, GPIbalpha, GPIb-IX, GPV, and CD31 were generated and characterized biochemically. MAbs against GPIb-IX, GPV, CD31, and linear epitopes on GPIIIa had mild and transient effects on platelet counts and induced no spontaneous bleeding. Anti-GPIbalpha mAbs induced profound irreversible thrombocytopenia (< 3% of normal) by Fc-independent mechanisms but only had minor effects on hematocrits. In contrast, injection of intact mAbs, but not F(ab)(2) fragments, against conformational epitopes on GPIIbIIIa, induced irreversible thrombocytopenia, acute systemic reactions, hypothermia, decreased hematocrits, and a paradoxical loss of surface GPIIbIIIa on platelets in vivo, the latter suggesting the formation of platelet-derived microparticles. Blockage of platelet-activating factor receptors inhibited the acute reactions, but not thrombocytopenia, loss of GPIIbIIIa, and decreases in hematocrits. Repeated injections of low doses of anti-GPIIbIIIa antibodies resulted in profound thrombocytopenia and bleeding, whereas no acute systemic reactions were observed. These data strongly suggest that the identity of the target antigen recognized by antiplatelet antibodies determines the mechanisms of platelet destruction and the severity of bleeding in mice, the latter depending on previously unrecognized anti-GPIIbIIIa-specific inflammatory mechanisms.


  • Open Access

    Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice

    by Bernhard Nieswandt, Wolfgang Bergmeier, Kirsten Rackebrandt, J. Engelbert Gessner, Hubert Zirngibl

    The pathogenic effects of antiplatelet antibodies were investigated in mice. Monoclonal antibodies (mAbs) of different immunoglobulin G subclass directed against mouse GPIIbIIIa, GPIIIa, GPIbα, GPIb-IX, GPV, and CD31 were generated and characterized biochemically. MAbs against GPIb-IX, GPV, CD31, and linear epitopes on GPIIIa had mild and transient effects on platelet counts and induced no spontaneous bleeding. Anti-GPIbα mAbs induced profound irreversible thrombocytopenia (< 3% of normal) by Fc-independent mechanisms but only had minor effects on hematocrits. In contrast, injection of intact mAbs, but not F(ab)2 fragments, against conformational epitopes on GPIIbIIIa, induced irreversible thrombocytopenia, acute systemic reactions, hypothermia, decreased hematocrits, and a paradoxical loss of surface GPIIbIIIa on platelets in vivo, the latter suggesting the formation of platelet-derived microparticles. Blockage of platelet-activating factor receptors inhibited the acute reactions, but not thrombocytopenia, loss of GPIIbIIIa, and decreases in hematocrits. Repeated injections of low doses of anti-GPIIbIIIa antibodies resulted in profound thrombocytopenia and bleeding, whereas no acute systemic reactions were observed. These data strongly suggest that the identity of the target antigen recognized by antiplatelet antibodies determines the mechanisms of platelet destruction and the severity of bleeding in mice, the latter depending on previously unrecognized anti-GPIIbIIIa-specific inflammatory mechanisms.


  • Open Access

    Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice

    by Bernhard Nieswandt, Wolfgang Bergmeier, Kirsten Rackebrandt, J. Engelbert Gessner, Hubert Zirngibl

    The pathogenic effects of antiplatelet antibodies were investigated in mice. Monoclonal antibodies (mAbs) of different immunoglobulin G subclass directed against mouse GPIIbIIIa, GPIIIa, GPIbα, GPIb-IX, GPV, and CD31 were generated and characterized biochemically. MAbs against GPIb-IX, GPV, CD31, and linear epitopes on GPIIIa had mild and transient effects on platelet counts and induced no spontaneous bleeding. Anti-GPIbα mAbs induced profound irreversible thrombocytopenia (< 3% of normal) by Fc-independent mechanisms but only had minor effects on hematocrits. In contrast, injection of intact mAbs, but not F(ab)2 fragments, against conformational epitopes on GPIIbIIIa, induced irreversible thrombocytopenia, acute systemic reactions, hypothermia, decreased hematocrits, and a paradoxical loss of surface GPIIbIIIa on platelets in vivo, the latter suggesting the formation of platelet-derived microparticles. Blockage of platelet-activating factor receptors inhibited the acute reactions, but not thrombocytopenia, loss of GPIIbIIIa, and decreases in hematocrits. Repeated injections of low doses of anti-GPIIbIIIa antibodies resulted in profound thrombocytopenia and bleeding, whereas no acute systemic reactions were observed. These data strongly suggest that the identity of the target antigen recognized by antiplatelet antibodies determines the mechanisms of platelet destruction and the severity of bleeding in mice, the latter depending on previously unrecognized anti-GPIIbIIIa-specific inflammatory mechanisms.


  • Open Access

    Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies

    by Wolfgang Bergmeier, Kirsten Rackebrandt, Werner Schröder, Hubert Zirngibl, Bernhard Nieswandt

    Five novel monoclonal antibodies (mAbs; p0p 1-5) were used to characterize the structural and functional properties and the in vivo expression of the murine GPIb-IX complex (von Willebrand factor receptor). The molecular weights of the subunits are similar to the human homologs: GPIb (150 kd), GPIbβ (25 kd), and GPIX (25 kd). Activation of platelets with thrombin or PMA predominantly induced shedding of glycocalicin (GC; 130 kd) but only low levels of receptor internalization. The GC concentration in normal mouse plasma was found to be at least 10 times higher than that described for human plasma (approximately 25 μg/mL versus 1-2 μg/mL). Two additional cleavage sites for unidentified platelet-derived proteases were found on GPIb, as demonstrated by the generation of 3 N-terminal fragments during in vitro incubation of washed platelets (GC, 60 kd, 45 kd). Occupancy of GPIb with p0p mAbs or F(ab)2-fragments resulted in aggregate formation in vitro and rapid irreversible thrombocytopenia in vivo, irrespective of the exact binding epitopes of the individual antibodies. GPIb-IX was not detectable immunohistochemically on endothelial cells in the major organs under normal or inflammatory conditions. The authors conclude that the mouse system might become an interesting model for studies on GPIb-IX function and regulation.